Beam Therapeutics Inc (BEAM)

$22.54 0.30 (1.35%)

16:00 EDT BEAM Stock Quote Delayed 30 Minutes

Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine

By Jeremy Flint, InvestorPlace Contributor May 9, 2024

These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot.

BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q1 2024

3 Biotech Stocks to Buy on the Dip: February 2024

Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market

Volume:

Previous Close -

Market Cap 1.79B

PE Ratio -20.87

EPS -1.08

Volume (Avg. Vol.) 1.19M

Day's Range $22.02 - $22.82

52-Week Range $16.95 - $49.50

Dividend & Yield N/A (N/A)

BEAM Stock Predictions, Articles, and Beam Therapeutics Inc News

From InvestorPlace
From the Web

3 Stocks to Buy in the Booming Field of Gene Editing

By Chris Markoch, InvestorPlace Contributor Jan 11, 2024

As the promise of gene editing moves closer to being a reality, these gene editing stocks have the opportunity for long-term gains.

The 3 Best Gene Editing Stocks on the Frontier of Medicine

By Ian Cooper, InvestorPlace Contributor Nov 20, 2023

Some of the best gene editing stocks could soon see a massive boost from these two massive catalysts in December.

Inside Cathie Wood’s Portfolio: 3 Stocks She Is Betting Millions On

By Yiannis Zourmpanos, InvestorPlace Contributor Nov 1, 2023

Are you looking to invest in disrupting stocks like Cathie Woods? Here are three stocks Cathie Wood is betting millions on.

7 Best Cathie Wood Stocks for Your May 2023 Buy List

By Alex Sirois, InvestorPlace Contributor May 2, 2023

This year promises to be very different for Cathie Wood stocks, as signs of economic improvement become more prominent.

The 3 Most Promising Gene Editing Stocks to Buy in 2023

By John Blankenhorn, InvestorPlace Contributor Apr 28, 2023

Intellia, Beam, and Editas are using gene editing to cure incurable diseases. These are three gene editing stocks you'll want to invest in.

3 Stocks to Watch in April: Is it Time to Buy?

By Josh Enomoto, InvestorPlace Contributor Apr 18, 2023

With several fundamental factors pushing against the equities sector, these stocks to watch in particular draw significant intrigue.

7 Top Growth Stocks to Buy for the Next Decade

By Alex Sirois, InvestorPlace Contributor Apr 18, 2023

These Growth Stocks to Buy Don't Require a 10-year Horizon But Should be More Valuable Then

7 Biotech Stocks to Buy for Breakthrough Treatments and Cures

By Josh Enomoto, InvestorPlace Contributor Mar 29, 2023

For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine.

3 CRISPR Gene Editing Stocks to Consider for Ground-Floor Investing

By John Blankenhorn, InvestorPlace Contributor Mar 6, 2023

CRISPR Therapeutics, Beam Therapeutics and Vertex Pharmaceuticals are three CRISPR gene editing stocks you won't want to miss out on.

The Top 7 Growth Stocks in Biotech

By Alex Sirois, InvestorPlace Contributor Mar 3, 2023

The biotech sector always houses a great selection of growth stocks that can grow rapidly and reward investors over the long-term.

7 CRISPR Stocks With the Best Long-Term Potential

By Alex Sirois, InvestorPlace Contributor Jan 30, 2023

CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.

7 ‘Next Big Things’ for Investors to Buy for 2023

By Chris Lau, InvestorPlace Contributor Dec 13, 2022

The next big thing for investors in 2023 is buying companies with revenue expansion amid what could be a painful economic slowdown.

5 Cathie Wood Stocks Signaling “The Bear Market Is Over”

By Thomas Yeung, CFA, InvestorPlace Markets Analyst Aug 22, 2022

These top Cathie Wood stocks are signalling that the bear market is over. For savvy investors, that presents a chance to profit.

Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today?

By Shrey Dua, InvestorPlace Assistant News Writer Aug 3, 2022

Gene editing stocks are a bright spot on the market today after Alnylam announced the success of one of its RNAi therapies, Patisiran.

Beam Therapeutics (BEAM) Stock Drops 4% on Clinical Hold News

By William White, InvestorPlace Writer Aug 1, 2022

Beam Therapeutics (BEAM) stock is slipping on Monday after the U.S. Food and Drug Administration placed a clinical hold on one of its drugs.

4 Undervalued Biotech Stocks to Add to Your Buy List

By Shanthi Rexaline Apr 20, 2022

These biotech stocks have seen their valuations tumble in the year-to-date sell-off. But they have the wherewithal to bounce big and generate decent, market-beating returns.

7 Gene Editing Stocks Promising to Change our DNA

By Chris Markoch, InvestorPlace Contributor Sep 15, 2021

Gene editing stocks will take off as the underlying tech moves from fiction to fact and companies put their products on the market.

Forget About the Genomic Revolution, the Proteomic Revolution Is Coming

By Luke Lango, InvestorPlace Senior Investment Analyst Sep 3, 2021

Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing.

Forget About the Genomic Revolution, the Proteomic Revolution Is Coming

By Luke Lango, InvestorPlace Senior Investment Analyst Sep 3, 2021

Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing.

Investing in CRISPR Stocks: Ultimate Genetic Editing Guide

By Luke Lango, InvestorPlace Senior Investment Analyst Jul 5, 2021

The biotech space is on the verge of hypergrowth, thanks to a scientific breakthrough in genetic editing. This is your ultimate guide to understanding and profiting from CRISPR stocks.

Beam Therapeutics Inc (BEAM)

Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine

BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q1 2024

3 Biotech Stocks to Buy on the Dip: February 2024

Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Beam Therapeutics Inc (BEAM)

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

BEAM Stock Predictions, Articles, and Beam Therapeutics Inc News

Subscriber Sign in